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Edited by Horst FeldmannAbstract More than 20 matrix metalloproteinases (MMPs)
and four of their endogenous tissue inhibitors (TIMPs) act
together to control tightly temporally restricted, focal proteol-
ysis of extracellular matrix. In the neurons of the adult brain
several components of the TIMP/MMP system are expressed
and are responsive to changes in neuronal activity. Furthermore,
functional studies, especially involving blocking of MMP activ-
ities, along with the identiﬁcation of MMP substrates in the
brain strongly suggest that this enzymatic system plays an
important physiological role in adult brain neurons, possibly
being pivotal for neuronal plasticity.
 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Matrix metalloproteinases (MMPs) are a family of enzymes
with more than 20 members identiﬁed to date that are all ex-
tracellular (predominantly secreted pericellularly, and some
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sclerosis; A2RE, A2 response element; BDNF, brain-derived neuro-
trophic factor; CA, cornu Ammoni; CDV, canine distemper virus;
CNS, central nervous system; CREB, cAMP responsive element
binding (protein, a transcription factor); CSPG, chondroitin sulfate
proteoglycan; DG, dentate gyrus; ECM, extracellular matrix; ECS,
electroconvulsive seizures; ER, endoplasmic reticulum; HSPG, hepa-
ran sulfate proteoglycan; KA, kainate; LRP, low-density lipoprotein
receptor-related protein; LTP, long term potentiation; L1, outer layer
of the cerebral cortex; MMP, matrix metalloproteinase; MT-MMP,
membrane-type matrix metalloproteinase; NGF, nerve growth factor;
NO, nitric oxide; PD, Parkinson’s disease; PGs, proteoglycans; RT-
PCR, reverse-transcriptase polymerase chain reaction; TIMP, tissue
inhibitor of matrix metalloproteinases; tPA, tissue plasminogen
activator; uPA, urokinase plasminogen activator; uPAR, uPAR
receptor
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.03.070enzymatic activity [1]. Their major targets are proteins of the
extracellular matrix (ECM). MMPs are grouped together be-
cause of their sequence homology and resulting structural and
enzymatic similarities [1,2]. MMPs are enzymatically activated
by means of the cleavage of the propeptide [1,3,4]. Once
activated, the MMPs are subject to inhibition by the tissue
inhibitors of metalloproteinases (TIMPs) that bind MMPs
non-covalently. There are four TIMPs identiﬁed so far: TIMP-
1, -2, -3, and -4.
The regulation of MMPs’ expression and activity appears to
be a very complex process. In an exemplary case of MMP-9,
the following steps can be delineated (Fig. 1), as indicated by
collective evidence obtained in various cell types and tissues.
There are a number of gene regulatory sequences driving the
MMP-9 expression, with AP-1 and NF-jB being the most
prominent [5]. Once produced, the MMP-9 mRNA is subjected
to regulation at its stability level by nitric oxide (NO) [6]; as
well it can apparently be translocated in neurons towards ac-
tivated dendrites [7]. Notably, MMP-9 contains ARE-like se-
quences that have been suggested to be of pivotal importance
for the translocation in other messages [8].
The protein is synthesized with the signal peptide responsible
for a translocation to the endoplasmic reticulum, where the
signal peptide is removed. Glycosylation of MMP-9 protein
provides an additional level of regulation [9]. The next step is an
export of MMP-9 protein, in vesicles, to the extracellular space
[10]. The MMPs are produced by cells in an inactive form (pro-
MMP) where the cystein residue of the propeptide region is
bound to a zinc atom present in the catalytic domain. Fully
active protein is produced by disruption of the cysteine–zinc
interaction and enzymatic removal of the propeptide [1]. The
activation of the pro-enzyme is controlled by a cascade of steps
involving other MMPs and the plasmin system. For instance,
another MMP,MMP-2 (activated by aMMP bound by TIMP-
2) can activate pro-MMP-9 [11]. Thus, in this case TIMP-2
facilitates MMP activation. Furthermore, pro-MMP-9 can
form a complex with TIMP-1 that involves interaction of the C-
terminal (non-catalytic) domain of pro-MMP-9 and the C-ter-
minal (non-inhibitory) domain of TIMP-1. This complex can
interact with MMP-3 and then dissociate into free pro-MMP-9
and the TIMP-1–MMP-3 complex [1]. In addition, S-nitrosy-
lation of MMP-9 protein can also activate pro-MMP-9 [12].
Tissue type plasminogen activator (tPA), as well as uroki-
nase type plasminogen activator (uPA) are principal enzymes
releasing active plasmin that activates MMP-1 and -3, which inblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation of MMP-9 activation.
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MMP-9 also in a plasmin-independent manner, namely it has
been shown that tPA can bind to the low-density receptor-
related protein (LRP) and indirectly regulate MMP-9 gene
transcription [14]. LRP can also act as a receptor for MMP-9
that mediates internalization and degradation of the enzyme
[15]. Finally, MMP-9 activity can be inhibited by TIMPs [1].
The MMP–TIMP system has been well characterized in
normal development as well as in a number of pathological
conditions. In brief, MMPs are responsible for cell migration
and tissue penetration and TIMPs counteract these activities.
Much less is known about the enzymatic system in adult tissues
and brain neurons remain especially poorly understood in this
context. On the other hand, much more is known about MMPs
originating from glia, especially under pathological conditions
[3,4]. The purpose of this review is to present data on neuronal
MMPs in the adult brain in a hope that a synopsis of the
available information could help elucidate the physiologicalfunction of the system. We will focus on the MMP/TIMP ex-
pression patterns under basal conditions as well as following
neuronal stimulation with a special emphasis on conditions that
may reveal a beneﬁcial rather than a detrimental role of the
MMPs. The functional studies employing MMP inhibition will
also be evoked in the same context. It has to be noted that the
pathological involvement of MMPs has already been exten-
sively presented and discussed in the literature [3,4,16].2. TIMPs in the brain
All four TIMP genes have been shown to be expressed in un-
stimulated adult brain [17–23] (seeTable 1).TIMP-1mRNAand
protein have been found to be present in the hippocampus [19]
with mRNA detected in granule cells of the dentate gyrus (DG)
and pyramidal cells of CA1 and CA3 subﬁelds [20,24], whereas
TIMP-1 immunoreactivity was mostly associated with the main
Table 1
Basal and induced TIMP expression in the brain
Gene Brain structure Expression References
Basal level Upregulation/downregulation
TIMP-1 Hippocampus Pyramidal and granular neurons,
cell bodies and dendrites
Seizures (neurons, astrocytes)a [19,20,26,27]
ECS (DG, molecular layer of DG)a [24]
Early phase of CDV infectiona [32]
Transient ischemiaa [20]
Experimental autoimmune encephalitisa [23]
Human T-lymphotropic virus type I infectiona [29,33]
Human immunodeﬁciency 1-associated dementiaa [33]
Cortex Neurons, not astrocytes KCl depolarization (neurons)a [25]
ECS (outer layer of the cerebral cortex)a [24]
Early phase of CDV infectiona [32]
Cerebral contusiona [25]
Cerebellum Neurons, Bergman glial cells Changes during postnatal development [17,18,21]
Hypothalamus Early phase of CDV infectiona [32]
Substantia nigra Parkinson’s diseasea [31]
TIMP-2 Cortex Predominantly neurons Unaﬀected by KCl depolarization [23,25]
Cerebellum Neurons Changes during postnatal development [17]
TIMP-3 Cortex Predominantly neurons Unaﬀected by KCl depolarization [25]
Early phase of CDV infection in mousea [32]
Transient ischemiaa [73]
Cerebellum Neurons, dendrites, cell bodies Changes during postnatal development [17,18]
TIMP-4 Cerebellum Purkinje cells Changes during postnatal development [21]
aUpregulation of TIMP gene expression.
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layer, stratum oriens, radiatum and lucidum [20]. TIMP-1
mRNA expression was also described in cortical neurons [24,25]
and in the cerebellum [18,21], where Villant et al. [17] have found
TIMP-1 protein in the cell bodies of interneurons, Purkinje cells
andBergmanglia.Nedivi et al. [26]were theﬁrst toﬁnd increased
levels of TIMP-1 mRNA in the hippocampal DG following
seizures. Rivera et al. [19] and Jaworski et al. [27] extended this
observation, by documenting elevated TIMP-1 mRNA and
protein expression in all of the hippocampal subﬁelds, thus
suggesting that it is a neuronal response to the enhanced activity.
Furthermore, Rivera et al. [19] found that seizures elevate
TIMP-1 immunoreactivity in neuronal cell bodies and dendritic
areas at early time points after seizures and in astrocytes 3 days
after seizures, when the reactive gliosis is present. Gertten et al.
[25] have shown that expression of TIMP-1 mRNA increases in
cortical neurons after KCl-depolarization. Robust induction of
TIMP-1mRNAhas been observed after acute electroconvulsive
seizures (ECS) in neurons of theDGof the hippocampus and the
outer layer of the cerebral cortex (L1) [24]. After chronic ECS,
there is further induction in the L1 region, as well as an increase
in the molecular layer of the hippocampus. In pathological
conditions of brain damage evoked by ischemia [20,28] as well as
viral infections [29], elevation of TIMP-1 expression has also
been noted and suggested to have a neuroprotective potential. It
is also of great interest that TIMP-1 gene expression in the hip-
pocampus is regulated by AP-1 transcription factor, whose as-
sociation with neuronal plasticity, including learning and
memory, has been very extensively documented [27,30].
As far as the possible function of TIMP-1 in the brain is
concerned, very little is known. However, it should be noted
that this protein delivered in an adenoviral vector was capable
of inhibiting excitotoxic cell death in cultured neurons [28]. The
action of TIMP-1 was anti-necrotic rather than anti-apoptotic
as it was very fast (already within 1 h) and speciﬁc to glutamate-evoked neuronal loss, but not eﬀective against chemical-
induced ischemia or nerve growth factor (NGF) withdrawal.
Furthermore, blocking MMP activity using synthetic MMP
inhibitors as well as treatment with TIMP-3 oﬀered no neuro-
protection against excitotoxicity [28]. The possible mechanism
of TIMP-1 neuroprotection involves its ability to lower intra-
cellular calcium levels in response to glutamate [28].
TIMP-2 is the most abundantly expressed TIMP in the adult
CNS [21]. In the rat cerebellum both the mRNA and protein
are present in cell bodies of interneurons, Purkinje cells and
granular neurons in the internal granular layer [17,18]. In the
cortex expression of TIMP-2, mRNA is observed predomi-
nantly in neurons [23,25]. Notably, TIMP-2 expression ap-
pears to be neither upregulated by neuronal depolarization nor
by pathological conditions that activate TIMP-1 [23,31,32].
TIMP-3 is expressed at the lowest level in the adult rat brain
[21], although its mRNA has been found in the cortex [33],
cerebellum [17], thalamus, olfactory bulb [22], and brain stem
[18]. Immunohistochemistry has shown cerebellar TIMP-3
expression in the dendritic elongations of Purkinje cells and in
the granular neurons in the internal granular layer. In contrast,
TIMP-3 mRNA was only detected in the cell bodies of Pur-
kinje cells. Pagenstecher et al. [23] have shown that TIMP-3
mRNA is expressed in choroid plexus as well as in scattered
unidentiﬁed cells in the CA4 region of the hippocampus and in
some gigantocellular neurons in the brain stem. During viral
infections there is TIMP-3 mRNA and protein upregulation in
neurons within hours [32]. TIMP-3 protein is produced by
primary cultures of cortical neurons [34] and astrocytes [35].
Functionally, it has been shown that TIMP-3 may play a pro-
apoptotic role in a model of neuronal cell death evoked by
doxorubicin [34].
The least is known about TIMP-4 expression in the brain.
TIMP-4 mRNA is present in the cerebellum, cerebrum and
brain stem [18,21,36].
Table 2
Basal and induced MMP expression in the brain
Gene Brain structure Expression References
Basal level Upregulation/downregulation
MMP-2 Hippocampus Uniformly distributed,
gray matter, astrocytes
Unaﬀected by spatial learning [7,38]
Seizures (3–7 days)a [39,40]
Sproutinga [37]
Traumatic brain injurya [37]
Transient ischemiaa [20]
Early phase of CDV infectiona [32]
Cortex Astroglia, some neurons Seizures (3–7 days)a [39,40]
Transient ischemiaa [42]
ALSb [57]
Cerebellum Purkinje cells Changes during postnatal development [17]
Striatum [40,74]
Substantia nigra Parkinson’s diseaseb [31]
Pons Spinocerebellar ataxia type 3a [75]
MMP-3 Cortex Transient ischemiaa [43]
Traumatic brain injurya [46]
Cerebellum Neurons, cell bodies, Bergman
glia ﬁbers
Changes during postnatal development [17]
MMP-7 Brain More than three orders of
magnitude less than MMP-9
[76]
MMP-8 Brain Two orders of magnitude
less than MMP-9
[61,76]
MMP-9 Hippocampus Pyramidal and granular neurons,
cell bodies and dendrites
Seizures (neurons, dendrites, astrocytes)a [7,20,39–41]
Spatial learninga [38]
Sleep deprivationb [52]
Alzheimer’s diseasea [77]
Early phase of CDV infectiona [32]
Transient ischemiaa [20]
Cortex Cortical neurons (cytoplasm and
apical dendrites), white matter KCl
Seizuresa [39,40,42]
Spatial learninga [38]
Depolarization (neurons)a [25]
Modulated by sleep [52]
Cerebral contusiona [25]
ALSb [57]
Transient ischemiaa [12,42,43]
Striatum [20,42,74]
Cerebellum Neurons, granule cell precursors,
cell bodies, Bergman glial processes
Changes during postnatal development [17,38–40,53]
MMP-10 Brain Two orders of magnitude less than
MMP-9
[76]
MMP-11 Brain Similar amount as MMP-9 [76]
MMP-12 Cortex Traumatic brain injurya [46]
MMP-13 Brain Two orders of magnitude less than
MMP-9
[61,76]
MMP-14 Cortex Early phase of CDV infectiona [32]
Hypothalamus Early phase of CDV infectiona [32]
MMP-15 Brain Similar amount to MMP-9 [61,76]
MMP-16 Brain Similar amount to MMP-9 [61,76]
Nucleus accumbens Inducible by CREB transgene [78]
MMP-24 Hippocampus Pyramidal and granular neurons Changes during postnatal development [61–63]
Cortex Neurons Changes during postnatal development [61]
Cerebellum Neurons, cell bodies and dendrites Changes during postnatal development [61–63]
aUpregulation of MMP gene expression.
bDownregulation of MMP gene expression.
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Thus far, gelatinases (MMP-2 and MMP-9) have been the
most frequently investigated MMPs in the brain (see Table 2).This situation has probably been driven mostly by the fact that
they are relatively easily detectable and measurable by
zymography, both gel-based and in situ, in which the ability to
digest denatured collagen IV (gelatin) is employed.
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detected in various brain structures and reported to be prefer-
ably astroglial in origin [7,20,37–41]. In addition, Planas et al.
[42] found MMP-2 also in some cortical neurons, and neuronal
MMP-2 has also been described in the cerebellum, including the
Purkinje neurons [17,38–40]. In vitro studies have shown that
MMP-2 activity is produced by astrocytes and microglia [43],
oligodendrocytes [44,45] and even neurons [46]. However, it
shall be noted that neuronal cultures consist of very immature
populations of cells. It is thus interesting that MMP-2 is ex-
pressed at a much higher level during postnatal cortical devel-
opment than in the adult neocortex (Dzwonek et al.,
unpublished). Inducible expression of MMP-2 in glia has also
been noted following brain ischemia [20,42], kainate (KA)
treatment as well as traumatic and viral brain injury
[32,37,40,47–49]. Interestingly, Asahi et al. [50] showed that
MMP-2 gene knockout in mice has no eﬀect on brain injury
after permanent and transient focal ischemia. On the other
hand, stereotactical implantation of conditioned medium in-
cluding pro-MMP-2 to the mouse basal ganglia results in neu-
ronal death and neuroinﬂammation with ensuing behavioral
deﬁcits [48]. This pathological chain is abrogated by the MMP
activity inhibitory drug Prinomastat or by implantation of an
inactive MMP-2 Glu375Ala mutant. A potentially functional
role of MMP-2 in post-lesion axonal sprouting and neuronal
plasticity has been suggested by Reeves and colleagues, who
reported that deaﬀerentation and subsequent functional plastic
recovery of the entorhinal cortex projections to the hippocam-
pal DG correlate with increasedMMP-2 activity, and theMMP
inhibitor FN-439 prevents recovery [37,51]. However, it shall be
noted that the inhibitor is not MMP-2 speciﬁc.
In contrast to MMP-2, MMP-9 mRNA and protein ex-
pression [7,20,52] as well as its activity [7,20,38–40,53] have
been detected in the hippocampus, cerebellum and cortex,
predominantly in neurons. MMP-9 (at the protein and enzy-
matic activity levels) has been found mainly in cell bodies and
dendrites [7,42]. Furthermore, in vitro studies showed MMP-9
protein expression in the neuronal processes of cultured hip-
pocampal neurons [7]. A more limited level of MMP-9 ex-
pression has also been observed in glia, in particular in
astrocytes and microglia, both in vivo and in vitro [17,43–45].
Szklarczyk et al. [7] and Zhang et al. [40] have shown that
KA treatment results in upregulation of MMP-9 mRNA,
protein and enzymatic activity in hippocampal DG and neo-
cortex early after seizures (6–24 h). The exclusive hippocampal
localization of MMP-9 upregulation within the DG suggests
MMP-9 involvement in synaptic plasticity [54]. Most inter-
estingly, the enhanced mRNA expression was observed both in
the neuronal cell bodies as well as in dendritic layer, implying
an activity-driven translocation of the MMP-9 mRNA. Jour-
quin et al. [41] have shown that MMP-9, but not MMP-2,
activity is induced by KA in organotypic cultures of the hip-
pocampus. Furthermore, MMP-9 mRNA levels were increased
after KCl-depolarization in the cortex [25] and enzymatic ac-
tivity of MMP-9, but not MMP-2, was found to be elevated in
the rat hippocampus and prefrontal cortex in the course of
spatial learning [38]. On the other hand, MMP-9 mRNA level
decreases in the cerebral cortex after sleep deprivation whereas
after enhanced ambient temperature, a condition that pro-
motes sleep, increases [52]. During postnatal cerebellar devel-
opment, MMP-9 is expressed by granule and Purkinje neurons
of the cerebellum [53]. MMP-9 promotes cerebellar granule cellmigration and axonal growth during early postnatal life [53].
In this period cerebellar granule cell apoptosis coincides with
the initial period of synaptogenesis between parallel ﬁbers and
Purkinje cells. In MMP-9 deﬁcient mice, a decreased physio-
logical, granule cell apoptosis during the period is observed
[53], suggesting a potential connection(s) between neuronal
survival, synaptogenesis and MMP-9. These results show a
close association of MMP-9 expression with neuronal physi-
ology. Apparently, no functional data have been reported
speciﬁcally on MMP-9 and neuronal plasticity, despite the
availability of MMP-9 knockout mice. Those animals were,
however, used for brain damage studies, and it has been found
that lack of MMP-9 reduces the neurodegeneration evoked by
either ischemia or brain trauma [55,56]. This notion appears
surprising in the context of the previously described data im-
plicating MMP-9 in neuronal plasticity. However, although
under the variety of neurodegenerative conditions (ischemia,
brain trauma, viral infections, amyotrophic lateral sclerosis,
ALS, Parkinson’s disease, PD, Alzheimer’s disease, AD)
MMP-9 still remains mainly neuronal in origin, it is not clear
whether it is expressed by the neurons prone to death and/or
those attempting to recover from the damage [12,20,31,
32,43,57–59]. As it has recently been pointed out that both
possibilities should be equally considered [60].
MMP-24 (MT5-MMP) is the next member of the family,
whose expression was investigated in the brain by various re-
searchers. Sekine-Aizawa et al. [61] used an reverse-transcrip-
tase polymerase chain reaction (RT-PCR) approach to show
that MMP-24 comprises 60% of the total rat brain population
of the non-gelatinase MMPs. In the adult mouse brain strong
MMP-24 mRNA signals were detected in the DG of the hip-
pocampus, the granular layer of the cerebellum [61–63], the
olfactory bulb and the thalamus [61,63]. The presence of
MMP-24 protein was also detected by immunostaining at the
hippocampal pyramidal and granular neurons as well as in cell
bodies and dendrites of granule cells in the cerebellum [61,62].
In vitro studies have shown that MMP-24 is expressed at the
growth cone of neurons [62].
Among the other MMPs, less frequently studied in the brain
is MMP-3. Villant et al. [17] investigated MMP-3 protein ex-
pression in rat cerebellum. They found that MMP-3 is present
in cell bodies of interneurons, Purkinje cells, granular neurons
in the internal granular layer and in Bergman glia ﬁbers. MMP-
3 protein has also been found in cortical neurons [34] and as-
trocytes [35] in culture, however, Rosenberg et al. [43] could not
ﬁnd MMP-3 immunostaining in cerebral cortex of spontane-
ously hypertensive rats. Nevertheless, MMP-3 appeared in
neurons and activated microglia/macrophages of ischemic ce-
rebral cortex [43]. Non-ischemic neurons showed scattered and
punctuated MMP-3 immunopatterns, whereas ischemic ones
diﬀuse staining co-localized with cell bodies. MMP-3 induction
in brain pathology can be related to its anti-apoptotic action
exerted by shedding of the death receptors from neuronal cell
surface, thus abrogating apoptotic signaling [34].4. Proteins targeted by MMPs in brain neurons
Search for the MMPs’ target molecules can help discover
and explain MMPs’ role(s) in brain physiology. Two major
reasons make this task very challenging. First, the MMPs
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and their hic et nunc activity, temporally and spatially very
restricted, determines what is to be digested. Furthermore,
intraneuronal ECM of the adult brain does not contain the
classical ECM proteins like agrin, collagen, laminin or perl-
ecan reported to be susceptible to MMP activities in other
tissues [64]. Thus, there are virtually no well documented
physiological MMP target proteins, and just a handful of
pathological ones. According to the leading concept of this
review, we limit the description of the targets to those which
are expressed by brain neurons.
A very promising MMP physiological brain target molecule
is b-dystroglycan [65,66]. Dystroglycan is a cell surface protein
protruding from postsynaptic membrane and bound (probably
throughout the synaptic cleft) to presynaptic neurexins, im-
plicated in neurotransmitter release [64,67]. Genetic evidence
implicated dystroglycan in long term potentiation (LTP), a
model of neuronal plasticity [68]. These results and consider-
ations have prompted us to propose that MMP-9 can be in-
volved in synaptic plasticity by modifying the local
environment and even serve as a retrograde messenger at ac-
tivated synapses [66].
Amyloid peptide, a hallmark of AD could be another target
of MMP-9 in the brain. In the human AD hippocampus there
is an accumulation of MMP-9 zymogen in both the neurons as
well as senile plaques and neuroﬁbrillary tangles [58]. Fur-
thermore, upon incubation in vitro, activated MMP-9 cleaves
a synthetic b-amyloid peptide Ab 1–4 at several sites, especially
within the membrane spanning domain at Leu34–Met35,
generating a non-neurotoxic form of amyloid peptide [58].
Several substrates of potential physiological signiﬁcance
have been proposed for MMP-24. In vitro, this enzyme cleaves
proteoglycans (PGs), including chondroitin sulfate proteogly-
can (CSPG) [69]. In the mouse brain similar cleavage also
occurs and CSPG together with heparan sulfate proteoglycan
(HSPG) could comprise the MMP-24 targets [62]. PGs,
abundant brain ECM molecules, regulate synaptogenesis in-
hibiting neurite extension and, therefore, can also be involved
in synaptic plasticity. In a neurite extension assay, MMP-24
eliminates the inhibitory eﬀect of HSPG or CSPG on the
neurite outgrowth without hindering the neurite-promoting
potential of laminin. The action of MMP-24 is blocked by its
activity inhibitor BB-94. It should not remain overlooked that
MMP-24 can activate other MMP zymogens, e.g., MMP-2
[69]. Thus it is possible that MMP-24 may exert the afore-
mentioned eﬀects indirectly. Interestingly, neuronal MMP-2
degrades CSPG in vitro in regenerating chicken embryonic
root ganglionic neurons playing an important role in the re-
generation of peripheral nerves [70].
It is well established that neurotrophins such as NGF and
brain-derived neurotrophic factor (BDNF) participate in
neuronal survival and synaptic plasticity. Their precursors
contain consensus sites for cleavage by MMP-3 and MMP-7
[71]. Indeed, the proteases can extracellularly cleave secreted
pro-neurotrophins [72].5. Concluding remarks
TIMPs and MMPs display distinct expression patterns in
adult brain neurons, and their levels are regulated by neuronal
activity, clearly implicating speciﬁc components of the TIMP/MMP system in neuronal physiology. Results from subcellular
localization as well as functional studies point to possible
role(s) of TIMPs and MMPs in axonal, dendritic and synaptic
functions. Altogether these data suggest that, besides playing
well documented roles in neuronal pathologies, selective
members of TIMP and MMP families are important for neu-
ronal plasticity. Recent rapid development of the tools al-
lowing to approach the TIMP/MMP system functionally
should greatly facilitate further studies aiming at the elucida-
tion of their physiological functions. It remains especially in-
triguing whether activated MMPs play detrimental and/or
beneﬁcial roles in response to neuronal damage. Other major
questions to be addressed in future studies are those about
regulation of MMPs’ and TIMPs’ expression and function, as
well as deﬁning their physiological partners and targets.
Clearly, we are just witnessing an opening of studies on this
important enzymatic system in brain physiology.
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